| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gene-expression profiles predict survival of patients with lung adenocarcinoma.
|
Nat Med
|
2002
|
21.28
|
|
2
|
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.
|
Cancer Res
|
2013
|
2.27
|
|
3
|
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis.
|
Oncogene
|
2005
|
1.99
|
|
4
|
Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis.
|
Am J Pathol
|
2003
|
1.92
|
|
5
|
Protein profiles associated with survival in lung adenocarcinoma.
|
Proc Natl Acad Sci U S A
|
2003
|
1.86
|
|
6
|
Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.
|
Immunity
|
2013
|
1.77
|
|
7
|
Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling.
|
Clin Cancer Res
|
2009
|
1.76
|
|
8
|
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors.
|
Clin Cancer Res
|
2002
|
1.67
|
|
9
|
RANTES expression is a predictor of survival in stage I lung adenocarcinoma.
|
Clin Cancer Res
|
2002
|
1.67
|
|
10
|
An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer.
|
Nat Biotechnol
|
2009
|
1.47
|
|
11
|
Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas.
|
Proc Natl Acad Sci U S A
|
2005
|
1.44
|
|
12
|
Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas.
|
J Pathol
|
2004
|
1.41
|
|
13
|
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.
|
J Clin Oncol
|
2009
|
1.38
|
|
14
|
Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
|
J Clin Endocrinol Metab
|
2008
|
1.37
|
|
15
|
Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma.
|
Cancer Res
|
2004
|
1.35
|
|
16
|
Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology.
|
Am J Surg Pathol
|
2013
|
1.29
|
|
17
|
Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma.
|
Neoplasia
|
2006
|
1.28
|
|
18
|
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.
|
Clin Cancer Res
|
2006
|
1.27
|
|
19
|
Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.
|
Cancer Res
|
2007
|
1.26
|
|
20
|
Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin.
|
Am J Pathol
|
2012
|
1.23
|
|
21
|
Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma.
|
Mod Pathol
|
2006
|
1.23
|
|
22
|
CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma.
|
Clin Cancer Res
|
2010
|
1.23
|
|
23
|
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.
|
Clin Cancer Res
|
2010
|
1.23
|
|
24
|
Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas.
|
Oncogene
|
2003
|
1.20
|
|
25
|
Distinct gene expression profiles of viral- and nonviral-associated merkel cell carcinoma revealed by transcriptome analysis.
|
J Invest Dermatol
|
2012
|
1.14
|
|
26
|
Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma.
|
Proc Natl Acad Sci U S A
|
2012
|
1.12
|
|
27
|
Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas.
|
Mol Cell Proteomics
|
2003
|
1.11
|
|
28
|
Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity.
|
Clin Cancer Res
|
2010
|
1.07
|
|
29
|
Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma.
|
Transl Oncol
|
2010
|
1.06
|
|
30
|
Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition.
|
Pediatr Blood Cancer
|
2006
|
1.04
|
|
31
|
Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.
|
Eur J Cancer
|
2012
|
1.02
|
|
32
|
Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis.
|
J Invest Dermatol
|
2013
|
1.00
|
|
33
|
Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice.
|
Endocrinology
|
2009
|
1.00
|
|
34
|
Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma.
|
Neoplasia
|
2009
|
1.00
|
|
35
|
A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
|
Clin Cancer Res
|
2012
|
0.99
|
|
36
|
Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma.
|
Neoplasia
|
2002
|
0.98
|
|
37
|
Stromal LRP1 in lung adenocarcinoma predicts clinical outcome.
|
Clin Cancer Res
|
2011
|
0.98
|
|
38
|
L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma.
|
Neoplasia
|
2004
|
0.97
|
|
39
|
Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines.
|
Cancer
|
2007
|
0.96
|
|
40
|
Sporadic versus Radiation-Associated Angiosarcoma: A Comparative Clinicopathologic and Molecular Analysis of 48 Cases.
|
Sarcoma
|
2013
|
0.95
|
|
41
|
Dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features.
|
Am J Surg Pathol
|
2010
|
0.92
|
|
42
|
Characterization of vitamin D receptor (VDR) in lung adenocarcinoma.
|
Lung Cancer
|
2012
|
0.91
|
|
43
|
p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.
|
Histopathology
|
2012
|
0.90
|
|
44
|
Can lymphangiosarcoma be resurrected? A clinicopathological and immunohistochemical study of lymphatic differentiation in 49 angiosarcomas.
|
Histopathology
|
2010
|
0.90
|
|
45
|
Ewing sarcoma of the kidney: case series and literature review of an often overlooked entity in the diagnosis of primary renal tumors.
|
Urology
|
2013
|
0.90
|
|
46
|
Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.
|
Cancer
|
2006
|
0.90
|
|
47
|
Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma.
|
J Clin Oncol
|
2003
|
0.90
|
|
48
|
Cluster analysis of immunohistochemical markers in leiomyosarcoma delineates specific anatomic and gender subgroups.
|
Cancer
|
2009
|
0.89
|
|
49
|
Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping.
|
Mol Cell Proteomics
|
2006
|
0.89
|
|
50
|
Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants.
|
Clin Cancer Res
|
2004
|
0.88
|
|
51
|
INHBA overexpression promotes cell proliferation and may be epigenetically regulated in esophageal adenocarcinoma.
|
J Thorac Oncol
|
2009
|
0.88
|
|
52
|
Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation.
|
Oncologist
|
2008
|
0.86
|
|
53
|
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
|
Clin Cancer Res
|
2007
|
0.85
|
|
54
|
CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.
|
Lung Cancer
|
2013
|
0.84
|
|
55
|
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
|
Cancer
|
2007
|
0.84
|
|
56
|
Cluster analysis of immunohistochemical profiles delineates CK7, vimentin, S100A1 and C-kit (CD117) as an optimal panel in the differential diagnosis of renal oncocytoma from its mimics.
|
Histopathology
|
2011
|
0.83
|
|
57
|
Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
|
Mol Cancer Ther
|
2013
|
0.83
|
|
58
|
Proteomic analysis of eIF-5A in lung adenocarcinomas.
|
Proteomics
|
2003
|
0.83
|
|
59
|
Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model.
|
Clin Cancer Res
|
2011
|
0.82
|
|
60
|
Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas.
|
Proteomics Clin Appl
|
2008
|
0.82
|
|
61
|
Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma.
|
Genes Chromosomes Cancer
|
2006
|
0.81
|
|
62
|
Differential protein mapping of ovarian serous adenocarcinomas: identification of potential markers for distinct tumor stage.
|
J Proteome Res
|
2009
|
0.81
|
|
63
|
Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.
|
Am J Clin Oncol
|
2013
|
0.79
|
|
64
|
MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer.
|
Sci Rep
|
2015
|
0.78
|
|
65
|
Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
|
Int J Clin Exp Pathol
|
2012
|
0.77
|
|
66
|
Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors.
|
Am J Clin Pathol
|
2013
|
0.76
|
|
67
|
Estrogen receptor expression is high but is of lower intensity in tubular carcinoma than in well-differentiated invasive ductal carcinoma.
|
Arch Pathol Lab Med
|
2014
|
0.75
|
|
68
|
TGM2: a cell surface marker in esophageal adenocarcinomas.
|
J Thorac Oncol
|
2014
|
0.75
|
|
69
|
Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma.
|
Appl Immunohistochem Mol Morphol
|
2014
|
0.75
|
|
70
|
Cholecystokinin receptor positivity in children with chronic acalculous gallbladder dysfunction: a pilot study to investigate the etiology of chronic acalculous gallbladder dysfunction.
|
J Pediatr Surg
|
2008
|
0.75
|
|
71
|
Diagnostic evaluation of metastatic rhabdomyosarcoma in effusion specimens.
|
Diagn Cytopathol
|
2013
|
0.75
|
|
72
|
Central diabetes insipidus due to cytomegalovirus infection of the hypothalamus in a patient with acquired immunodeficiency syndrome: a clinical, pathological, and immunohistochemical case study.
|
J Clin Endocrinol Metab
|
2003
|
0.75
|
|
73
|
Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.
|
Cell Chem Biol
|
2017
|
0.75
|